NO20072051L - Nye pyrimidinderivater og deres anvendelse som PPAR-alfa modulatorar - Google Patents

Nye pyrimidinderivater og deres anvendelse som PPAR-alfa modulatorar

Info

Publication number
NO20072051L
NO20072051L NO20072051A NO20072051A NO20072051L NO 20072051 L NO20072051 L NO 20072051L NO 20072051 A NO20072051 A NO 20072051A NO 20072051 A NO20072051 A NO 20072051A NO 20072051 L NO20072051 L NO 20072051L
Authority
NO
Norway
Prior art keywords
pyrimidine derivatives
ppar
novel pyrimidine
alpha modulators
therapy
Prior art date
Application number
NO20072051A
Other languages
English (en)
Inventor
Hilmar Bischoff
Klemens Lustig
Claudia Hirth-Dietrich
Elke Dittrich-Wengenroth
Armin Kern
Ulrich Rosentreter
Dieter Lang
Lars Barfacker
Axel Kretschmer
Peter Ellinghaus
Martin Raabe
Christian Pilger
Stephan Bartel
Marcus Bauser
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of NO20072051L publication Critical patent/NO20072051L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Det beskrives nye pyrimidinderivater med den generelle formel (I), fremgangsmåter for fremstilling derav, deres anvendelse for terapi og/eller prevensjon av sykdommer og deres anvendelse for fremstilling av medikamenter for terapi og/eller prevensjon av sykdommer, særlig for terapi og/eller prevensjon av kardiovaskulære sykdommer og særlig dyslipidemi, arteriosklerose, hjerteinsuffisiens, trombose og metabolsk syndrom.
NO20072051A 2004-09-25 2007-04-20 Nye pyrimidinderivater og deres anvendelse som PPAR-alfa modulatorar NO20072051L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004046623A DE102004046623A1 (de) 2004-09-25 2004-09-25 Neue Pyrimidin-Derivate und ihre Verwendung
PCT/EP2005/009734 WO2006032384A1 (de) 2004-09-25 2005-09-10 Neue pyrimidin-derivate und ihre verwendung als ppar-alpha-modulatoren

Publications (1)

Publication Number Publication Date
NO20072051L true NO20072051L (no) 2007-06-07

Family

ID=35063041

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072051A NO20072051L (no) 2004-09-25 2007-04-20 Nye pyrimidinderivater og deres anvendelse som PPAR-alfa modulatorar

Country Status (22)

Country Link
US (1) US20080261990A1 (no)
EP (1) EP1797045A1 (no)
JP (1) JP2008514559A (no)
KR (1) KR20070055621A (no)
CN (1) CN101065364A (no)
AR (1) AR051295A1 (no)
AU (1) AU2005287589A1 (no)
BR (1) BRPI0517327A (no)
CA (1) CA2582492A1 (no)
DE (1) DE102004046623A1 (no)
EC (1) ECSP077340A (no)
GT (1) GT200500266A (no)
IL (1) IL182136A0 (no)
MA (1) MA28882B1 (no)
MX (1) MX2007003428A (no)
NO (1) NO20072051L (no)
PE (1) PE20060657A1 (no)
RU (1) RU2007115215A (no)
SV (1) SV2007002235A (no)
TW (1) TW200628451A (no)
UY (1) UY29127A1 (no)
WO (1) WO2006032384A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743001B (zh) * 2007-04-13 2013-02-06 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
KR100813387B1 (ko) * 2007-06-26 2008-03-12 신명곤 부형제 첨가없이 인삼농축액으로 유동성 및 저장성이우수한 인삼농축액환 제조 방법
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2012030165A2 (ko) 2010-08-31 2012-03-08 서울대학교산학협력단 P P A R δ 활성물질의 태자재프로그래밍용도
CA2852957C (en) 2011-10-28 2020-08-04 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
CA2853285C (en) 2011-10-28 2020-05-05 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
CN103130732A (zh) * 2011-11-22 2013-06-05 上海博康精细化工有限公司 3,5-二甲基-4-氯甲基异噁唑的制备方法
KR20160002773A (ko) 2013-03-15 2016-01-08 루메나 파마수티컬즈, 인코포레이티드 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
RU2015139732A (ru) 2013-03-15 2017-04-24 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециркуляции желчных кислот для лечения пищевода барретта и гастроэзофагеальной рефлюксной болезни
WO2017190050A1 (en) * 2016-04-28 2017-11-02 Cornell University Inhibitors of soluble adenylyl cyclase
WO2020167964A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
CN115598267B (zh) * 2022-12-13 2023-05-09 山东省食品药品检验研究院 一种格列齐特中潜在遗传毒性杂质的分析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU72201A (sh) * 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
GB0214254D0 (en) * 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
IL182136A0 (en) 2007-07-24
TW200628451A (en) 2006-08-16
DE102004046623A1 (de) 2006-03-30
RU2007115215A (ru) 2008-11-10
AR051295A1 (es) 2007-01-03
AU2005287589A1 (en) 2006-03-30
US20080261990A1 (en) 2008-10-23
WO2006032384A1 (de) 2006-03-30
UY29127A1 (es) 2006-04-28
CN101065364A (zh) 2007-10-31
EP1797045A1 (de) 2007-06-20
GT200500266A (es) 2006-05-11
KR20070055621A (ko) 2007-05-30
BRPI0517327A (pt) 2008-10-07
MX2007003428A (es) 2008-03-13
ECSP077340A (es) 2007-04-26
MA28882B1 (fr) 2007-09-03
CA2582492A1 (en) 2006-03-30
JP2008514559A (ja) 2008-05-08
PE20060657A1 (es) 2006-08-12
SV2007002235A (es) 2007-03-20

Similar Documents

Publication Publication Date Title
NO20072051L (no) Nye pyrimidinderivater og deres anvendelse som PPAR-alfa modulatorar
NO20050579L (no) Indolinfenylsulfonamidderivater
NO20065904L (no) Terapeutiske forbindelser
NO20064584L (no) Tetrahydropyridoindolderivater
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
NO20063925L (no) Indazolderivater som inhibitorer av hormonsensitiv lipase
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
NO20071593L (no) Pyrimidinderivater
NO20076648L (no) Novel thiophene derivatives
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20092033L (no) Nye forbindelser
NO20071300L (no) Trifluormetylsubstituerte benzamider som kinaseinhibitorer.
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
NO20081844L (no) Terapeutiske forbindelser
NO20071504L (no) Pyrimidinderivanter.
NO20071074L (no) Substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
DK1771155T3 (da) Fremgangsmåde og sammensætning til behandling af rhinitis
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
TW200621765A (en) Substituted phenylaminothiazoles and their use
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
NO20065880L (no) 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application